Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Immunome, Inc. - Common Stock
(NQ:
IMNM
)
21.68
+0.18 (+0.84%)
Streaming Delayed Price
Updated: 3:10 PM EST, Feb 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Immunome, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
↗
February 22, 2026
Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.
Via
The Motley Fool
Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120%
↗
February 22, 2026
This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.
Via
The Motley Fool
Topics
Regulatory Compliance
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
↗
February 22, 2026
This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.
Via
The Motley Fool
Topics
Regulatory Compliance
Where Immunome Stands With Analysts
↗
September 22, 2025
Via
Benzinga
Where Immunome Stands With Analysts
↗
September 05, 2025
Via
Benzinga
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’
↗
September 05, 2025
Via
Stocktwits
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
↗
February 22, 2026
Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
↗
February 22, 2026
Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.
Via
The Motley Fool
Topics
Regulatory Compliance
Why Immunome Stock Surged Today
↗
December 15, 2025
The oncology specialist's targeted therapies could improve thousands of lives.
Via
The Motley Fool
Analyst Expectations For Immunome's Future
↗
November 08, 2024
Via
Benzinga
Evaluating Immunome: Insights From 4 Financial Analysts
↗
May 31, 2024
Via
Benzinga
Which stocks are gapping on Monday?
↗
December 15, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Why Is IMNM Stock Rising Today?
↗
December 15, 2025
Immunome stock is on track to open at its highest levels in over 20 months, after the company reported positive topline results from its global Phase 3 RINGSIDE trial for a treatment targeting a type...
Via
Stocktwits
This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
↗
September 22, 2025
Via
Benzinga
This GATX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
September 22, 2025
Via
Benzinga
This Netgear Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
↗
August 22, 2025
Via
Benzinga
Immunome (IMNM) Q2 Revenue Surges 382%
↗
August 06, 2025
Via
The Motley Fool
These stocks are moving in today's after hours session
↗
June 30, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
March 26, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
January 30, 2025
Via
Benzinga
Curious about the stocks that are showing activity after the closing bell on Wednesday?
↗
January 29, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
3 Small-Cap Stocks With Big Growth Potential
December 13, 2024
Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.
Via
MarketBeat
Topics
Economy
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
↗
November 08, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
October 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
October 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
October 01, 2024
Via
Benzinga
Immunome Stock Sees RS Rating Jump To 91
↗
August 20, 2024
Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.
Via
Investor's Business Daily
IMNM Stock Earnings: Immunome Misses EPS, Misses Revenue for Q2 2024
↗
August 12, 2024
IMNM stock results show that Immunome missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying
↗
May 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
May 21, 2024
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
